In the highly competitive market for inflammatory diseases such as Crohn's, pharma companies are looking for ways to maximise benefits of already approved drugs, as well as
UCB and Amgen’s osteoporosis drug Evenity has finally been approved in Europe, following a successful appeal against a regulatory rejection, to become the first new drug for the condition s
There’s a whole gang of pharma companies queueing up to steal market share from AbbVie’s mega-blockbuster Humira, and UCB’s contender bimekizumab is shaping up for a challenge with another
With medicine adherence still a major problem for pharma and healthcare systems, a collaboration between Cognitant Group and Addenbrooke’s Hospital –supported by grants from UCB and Pfizer
UCB/Amgen’s osteoporosis drug Evenity (romosozumab) looks set for approval in Europe after regulators finally recommended it, following a successful appeal against a rejection with help fro
